Latest news
Analyst Matt Phipps Maintains Buy on NewAmsterdam as PREVAIL Interim Design Bolsters Cardiovascular Efficacy Odds and Risk-Reward Profile - TipRanksTipRanks · Thu, 06 Aug 2026 23:36:05 GMTMatt Phipps Reiterates Buy on Insmed as Brinsupri Outperformance, Raised Guidance and Higher Peak Sales Outlook Strengthen Long-Term Growth Story - TipRanksTipRanks · Thu, 06 Aug 2026 18:36:05 GMTAnalyst Reaffirms Buy on Context Therapeutics, Citing Undervalued Pipeline and CTIM-76 as Key Long-Term Driver - TipRanksTipRanks · Thu, 06 Aug 2026 17:52:17 GMTAstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus - inklinkl · Mon, 03 Aug 2026 17:13:39 GMTAbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates - KELO-AMKELO-AM · Fri, 31 Jul 2026 15:31:52 GMTAbbVie (ABBV) Q2 2026 Earnings Call Transcript - FortuneFortune · Fri, 31 Jul 2026 07:00:00 GMTIncyte lifts annual revenue forecast after settlement with CMS - 1470 & 100.3 WMBD1470 & 100.3 WMBD · Tue, 28 Jul 2026 07:00:00 GMT